The present disclosure provides, inter alia, methods for treating a disease characterized by an abnormal level of m6dA in a subject, such as cancer, methods of modifying a nucleic acid from a cell, methods for identifying protein binding sites on DNA, methods of mediating DNA N6-adenine methylation, methods of modulating nucleosome organization and/or transcription in a cell, using MTA1c or any components thereof. The present disclosure also provides methods of generating a synthetic chromosome and synthetic chromosomes made by such methods. Pharmaceutical compositions comprising MTA1c or any components thereof and kits containing such compositions or for carrying out such processes are further provided. Eukaryotic cells, vectors and transgenic organisms comprising MTA1c or any components thereof are also provided. Synthetic chromosomes and methods of making same are also provided.

The present invention relates to a cell capable of producing a fluorinated, a chlorinated or a brominated compound, methods for producing fluorinated, chlorinated or brominated compounds in a cell and expression systems therefor.

Provided herein is a method of detecting the presence or absence of a single naturally- or synthetically-modified nucleobase in a polynucleotide molecule, which is achieved by first contacting the polynucleotide molecule with one or more reagents capable of attaching a detectable moiety to at least one nucleobase of the polynucleotide molecule or to a nucleobase adjacent to the modified nucleobase, thereby forming a labeled nucleobase, while the presence or absence of the modified nucleobase is determined by the attachment. The polynucleotide molecule is then assayed using a nanopore device to detection the presence or absence of the labeled nucleobase, wherein the detectable moiety attached to at least one nucleobase in the polynucleotide molecule has a molecular weight that ranges from 40 to 1,000 Daltons, and the average pore diameter in the nanopore device is no more than 5 nanometers.